These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 35751455)

  • 1. Siglec15 Checkpoint Blockade for Simultaneous Immunochemotherapy and Osteolysis Inhibition in Lung Adenocarcinoma Spinal Metastasis via a Hollow Nanoplatform.
    Liang H; Zhou L; Hu Z; Ge Y; Zhang T; Chen Q; Wang B; Lu S; Ding W; Dong J; Xue F; Jiang L
    Small; 2022 Jul; 18(29):e2107787. PubMed ID: 35751455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Siglec15 facilitates the progression of non-small cell lung cancer and is correlated with spinal metastasis.
    Liang H; Chen Q; Hu Z; Zhou L; Meng Q; Zhang T; Wang B; Ge Y; Lu S; Ding W; Zhou X; Li X; Lin H; Jiang L; Dong J
    Ann Transl Med; 2022 Mar; 10(6):281. PubMed ID: 35434017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
    Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
    J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor stroma Siglec15 expression is a poor prognosis predictor in colon adenocarcinoma.
    Zhan W; Bai F; Cai Y; Zhang J; Qin G; Xie Y; Deng Y
    J Cancer; 2023; 14(16):2998-3008. PubMed ID: 37859817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tumor microenvironment responsive biodegradable CaCO
    Liu Y; Pan Y; Cao W; Xia F; Liu B; Niu J; Alfranca G; Sun X; Ma L; de la Fuente JM; Song J; Ni J; Cui D
    Theranostics; 2019; 9(23):6867-6884. PubMed ID: 31660074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer.
    Li TJ; Jin KZ; Li H; Ye LY; Li PC; Jiang B; Lin X; Liao ZY; Zhang HR; Shi SM; Lin MX; Fei QL; Xiao ZW; Xu HX; Liu L; Yu XJ; Wu WD
    Cancer Lett; 2022 Apr; 530():142-155. PubMed ID: 35077803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor microenvironment responsive hollow mesoporous Co
    Huang J; Huang Y; Xue Z; Zeng S
    Biomaterials; 2020 Dec; 262():120346. PubMed ID: 32927232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients With Lung Adenocarcinoma.
    Gong Z; Jia Q; Chen J; Diao X; Gao J; Wang X; Zhu B
    J Thorac Oncol; 2019 May; 14(5):857-866. PubMed ID: 30768970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hollow MnO
    Yang G; Xu L; Chao Y; Xu J; Sun X; Wu Y; Peng R; Liu Z
    Nat Commun; 2017 Oct; 8(1):902. PubMed ID: 29026068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of three Siglec15-related immune and prognostic subtypes of breast-invasive cancer.
    Cao X; Zhou Y; Mao F; Lin Y; Zhou X; Sun Q
    Int Immunopharmacol; 2022 May; 106():108561. PubMed ID: 35151947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor microenvironment-responsive versatile "Trojan horse" theranostic nanoplatform for magnetic resonance imaging-guided multimodal synergistic antitumor treatment.
    Huang Q; Pan Y; Wang M; Liu Z; Chen H; Wang J; Zhao Z; Zhang Y
    Acta Biomater; 2022 Jul; 147():270-286. PubMed ID: 35595202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
    Zhu P; Jin Z; Kang G; Jia Y; Liu D; Zhang Q; Guo F; Jia Y; Jiao Y; Li J; Sun H; Ma X
    Cell Commun Signal; 2022 Aug; 20(1):121. PubMed ID: 35971127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
    Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
    Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
    [No Abstract]   [Full Text] [Related]  

  • 14. Hybrid Mesoporous MnO
    Han X; Zhou L; Zhuang H; Wei P; Li F; Jiang L; Yi T
    ACS Appl Mater Interfaces; 2022 Apr; 14(16):18031-18042. PubMed ID: 35426297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer.
    Dai X; Lu L; Deng S; Meng J; Wan C; Huang J; Sun Y; Hu Y; Wu B; Wu G; Lovell JF; Jin H; Yang K
    Theranostics; 2020; 10(20):9332-9347. PubMed ID: 32802195
    [No Abstract]   [Full Text] [Related]  

  • 16. The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis.
    Zhang LX; Gao J; Long X; Zhang PF; Yang X; Zhu SQ; Pei X; Qiu BQ; Chen SW; Lu F; Lin K; Xu JJ; Wu YB
    Mol Cancer; 2022 May; 21(1):110. PubMed ID: 35525959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticles (NPs)-mediated Siglec15 silencing and macrophage repolarization for enhanced cancer immunotherapy.
    Liu X; Zhang Q; Liang Y; Xiong S; Cai Y; Cao J; Xu Y; Xu X; Wu Y; Lu Q; Xu X; Luo B
    Acta Pharm Sin B; 2023 Dec; 13(12):5048-5059. PubMed ID: 38045048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
    Marinelli D; Mazzotta M; Scalera S; Terrenato I; Sperati F; D'Ambrosio L; Pallocca M; Corleone G; Krasniqi E; Pizzuti L; Barba M; Carpano S; Vici P; Filetti M; Giusti R; Vecchione A; Occhipinti M; Gelibter A; Botticelli A; De Nicola F; Ciuffreda L; Goeman F; Gallo E; Visca P; Pescarmona E; Fanciulli M; De Maria R; Marchetti P; Ciliberto G; Maugeri-Saccà M
    Ann Oncol; 2020 Dec; 31(12):1746-1754. PubMed ID: 32866624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Syngeneic tobacco carcinogen-induced mouse lung adenocarcinoma model exhibits PD-L1 expression and high tumor mutational burden.
    Stabile LP; Kumar V; Gaither-Davis A; Huang EH; Vendetti FP; Devadassan P; Dacic S; Bao R; Steinman RA; Burns TF; Bakkenist CJ
    JCI Insight; 2021 Feb; 6(3):. PubMed ID: 33351788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoclast-derived apoptotic bodies inhibit naive CD8
    Wu Y; Ai H; Xi Y; Tan J; Qu Y; Xu J; Luo F; Dou C
    Cell Rep Med; 2023 Sep; 4(9):101165. PubMed ID: 37607544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.